Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
LE LEGN Legend Biotech Corp FY ended Dec 31, 2025 | $19.88 | $7.35B | $7.16B | $1.03B | -$296.80M | -$296.80M | -24.54x | 7.15x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 12.05x | 1/4 | -$4.17B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 12.64x | 4/4 | $3.33B | $7.35 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -10.95x | 4/4 | $4.28B | $9.45 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
LE LEGN Legend Biotech Corp FY ended Dec 31, 2025 | $19.88 | $7.35B | $7.16B | $1.03B | -$296.80M | -$296.80M | -24.54x | 7.15x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 12.05x | 1/4 | -$4.17B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 12.64x | 4/4 | $3.33B | $7.35 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -10.95x | 4/4 | $4.28B | $9.45 | Peer averages are not economically meaningful for this method. |
